Annet Bouma-de Krijger

Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease.

M. Bots, P. Blankestijn, M. Vervloet, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients

M. Bots, P. Blankestijn, M. Vervloet, 2015, Journal of Nephrology.

Change in FGF23 concentration over time and its association with all-cause mortality in patients treated with haemodialysis or haemodiafiltration

M. Vervloet, M. Nubé, M. Grooteman, 2020, Clinical kidney journal.

Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients

F. Dekker, J. Jukema, T. Rabelink, 2014, BMC Nephrology.

Fibroblast growth factor 23: are we ready to use it in clinical practice?

M. Vervloet, Annet Bouma-de Krijger, 2020, Journal of Nephrology.

Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.

M. Landray, D. Wheeler, L. Holland, 2018, Journal of the American Society of Nephrology : JASN.

Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3

M. Vervloet, F. V. van Ittersum, P. T. ter Wee, 2019, Clinical kidney journal.

Neurosyphilis mimicking giant cell arteritis both clinically and microscopically

M. V. van Kasteren, Annet Bouma-de Krijger, Niels J. van Ruitenbeek, 2022, BMJ Case Reports.